Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer

•Bladder cancer with conventional urothelial and adjacent sarcomatoid morphology share a common ancestor.•The urothelial and sarcomatoid morphology often have a basal-like phenotype and the sarcomatoid morphology is frequently enriched for epithelial-to-mesenchymal transition.•Molecular profiles may...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Urologic oncology 2019-09, Vol.37 (9), p.573.e19-573.e29
Hauptverfasser: Genitsch, Vera, Kollár, Attila, Vandekerkhove, Gillian, Blarer, Jennifer, Furrer, Marc, Annala, Matti, Herberts, Cameron, Pycha, Armin, de Jong, Joep J., Liu, Yang, Krentel, Friedemann, Davicioni, Elai, Gibb, Ewan A., Kruithof-de Julio, Marianna, Wyatt, Alexander W., Seiler, Roland
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Bladder cancer with conventional urothelial and adjacent sarcomatoid morphology share a common ancestor.•The urothelial and sarcomatoid morphology often have a basal-like phenotype and the sarcomatoid morphology is frequently enriched for epithelial-to-mesenchymal transition.•Molecular profiles may suggest different treatment strategies for conventional urothelial and sarcomatoid morphology. The sarcomatoid morphology of muscle-invasive bladder cancer (MIBC) is associated with unfavorable prognosis. However, the genomic, transcriptomic, and proteomic relationship between conventional urothelial and synchronous sarcomatoid morphology is poorly defined. We compiled a cohort of 21 MIBC patients with components of conventional urothelial and adjacent sarcomatoid morphology within the same tumor focus. We performed comprehensive pathologic and immunohistochemical characterization and in 4 selected cases, subjected both morphologic components to targeted DNA sequencing and whole transcriptome analysis. Synchronous sarcomatoid and urothelial morphology from the same MIBC foci shared truncal somatic mutations, indicating a common ancestral clone. However, additional mutations or copy number alterations restricted to the either component suggested divergent evolution at the genomic level. This was confirmed at the transcriptome level since while the urothelial component exhibited a basal-like subtype (TCGA2014: cluster III, LundTax: basal/squamous-like), the sarcomatoid morphology was predominantly cluster IV (claudin-low). Protein expression was consistent with a basal-like phenotype in both morphologies in 18/21 of cases. However, most cases had evidence of active epithelial-to-mesenchymal transition (E-Cad ↓ and Zeb1 or TWIST1 ↑) from urothelial toward the sarcomatoid morphology. Drug response signatures nominated different targets for each morphology and proposed agents under clinical investigation in liposarcoma or other sarcoma. PD-L1 expression was higher in the sarcomatoid than the urothelial component. Conventional urothelial and adjacent sarcomatoid morphologies of MIBC arise from the same common ancestor and share a basal-like phenotype. However, divergence between the morphologies at the genome, transcriptome, and proteome level suggests differential sensitivity to therapy.
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2019.06.021